HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AZD3241

a myeloperoxidase inhibitor

Also Known As:

1-(2-(propan-2-yloxy)ethyl)-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo(3,2-d)pyrimidin-4-one

Networked: 4 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - AZD3241: 4
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - AZD3241: 4

Experts

1.	Farde, Lars: 2 articles (09/2015 - 06/2015)
2.	Halldin, Christer: 2 articles (09/2015 - 06/2015)
3.	Johnström, Peter: 2 articles (09/2015 - 06/2015)
4.	Varnäs, Katarina: 2 articles (09/2015 - 06/2015)
5.	Ahmad, Gulfam: 1 article (01/2020)
6.	Chami, Belal: 1 article (01/2020)
7.	Fong, Genevieve: 1 article (01/2020)
8.	Gao, Antony: 1 article (01/2020)
9.	Liu, Yuyang: 1 article (01/2020)
10.	San Gabriel, Patrick T: 1 article (01/2020)

Related Diseases

1.	Neurodegenerative Diseases (Neurodegenerative Disease) 09/01/2015 - "The results of the present study provide support for proof of mechanism of AZD3241 and warrant extended studies on the efficacy of AZD3241 in neurodegenerative disorders. " 11/01/2018 - "AZD3241 is a potent and selective myeloperoxidase inhibitor potentially for the treatment of a number of neurodegenerative disorders, including multiple system atrophy (MSA). "
2.	Hemorrhage 01/01/2020 - "Administered AZD3241 attenuated body weight loss (10% p<0.05) and improved clinical score (9 fold p<0.05; a score comprising the time-dependent assessment of stool consistency and extent of rectal bleeding), loss of colonic crypts (p<0.001), preserved surface epithelium (p<0.001) and enhanced expression of the transcription factor Nrf-2 (regulator of antioxidants) and enhanced expression of the downstream antioxidant response element haeoxygenase-1 (HO-1) in the colon tissue. "
3.	Colitis 01/01/2020 - "Overall, AZD3241 ameliorated the course and severity of experimental colitis through ameliorating MPO derived tissue damage and could be considered a potential therapeutic option, subject to further validation in chronic IBD models." 01/01/2020 - "The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis."
4.	Body Weight (Weight, Body) 01/01/2020 - "Administered AZD3241 attenuated body weight loss (10% p<0.05) and improved clinical score (9 fold p<0.05; a score comprising the time-dependent assessment of stool consistency and extent of rectal bleeding), loss of colonic crypts (p<0.001), preserved surface epithelium (p<0.001) and enhanced expression of the transcription factor Nrf-2 (regulator of antioxidants) and enhanced expression of the downstream antioxidant response element haeoxygenase-1 (HO-1) in the colon tissue. "
5.	Parkinson Disease (Parkinson's Disease) 09/01/2015 - "The purpose of this phase 2a randomized placebo controlled multicentre positron emission tomography study was to examine the effect of 8 weeks treatment with AZD3241 on microglia in patients with Parkinson's disease. " 09/01/2015 - "Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease." 09/01/2015 - "The reduction of (11)C-PBR28 binding to translocator protein in the brain of patients with Parkinson's disease after treatment with AZD3241 supports the hypothesis that inhibition of myeloperoxidase has an effect on microglia. "

Related Drugs and Biologics

1.	Peroxidase (Myeloperoxidase)
2.	Transcription Factors (Transcription Factor)
3.	Dextrans (Dextran)
4.	Antioxidants
5.	sodium sulfate (sodium bisulfate)
6.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)